Elder Pharma targets 20% growth in revenues this fiscal

02 Jan 2012 Evaluate

Elder Pharmaceuticals is looking 20% growth in revenues to around Rs 1,200 crore in the current fiscal on the back of new product launches. The company is targeting to achieve the growth in the domestic market by its existing strong range of branded products including Shelcal, Eldervit and Chymoral as well as further brand building of its new product range.

The Mumbai-based firm, which derives 95% of its revenues from the domestic market, is also expecting a better performance from its in-licensed brands and overseas subsidiaries. Last year, the company had a turnover of about Rs 1,000 crore on a consolidated basis with maximum traction in women's healthcare, wound care and the nutraceutical segments.

At present, the company has 24 in-licence agreements with various firms for the domestic market.

The company has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.

Peers
Company Name CMP
Sun Pharma Inds. 1805.95
Dr. Reddys Lab 1274.35
Cipla 1520.95
Zydus Lifesciences 931.80
Lupin 2100.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×